References: Pituitary Tumors

Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366:914-924.

Dorsey JF, Hollander AB, Alonso-Basanta M, et al. Chapter 66: Cancer of the central nervous system. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med. 2010;362:1846-1848.

Hornyak M, Couldwell WT. Multimodality treatment for invasive pituitary adenomas. Postgrad Med. 2009;121:168-176.

Klibanski A. Prolactinomas. N Engl J Med. 2010;362:1219-1226.

Lake MG, Krook LS, Cruz SV. Pituitary adenomas: An overview. Am Fam Physician. 2013;88:319-327.

Lamberts SW, Hofland LJ. Future treatment strategies of aggressive pituitary tumors. Pituitary. 2009;12:261-264.

Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96:1992-2003.

National Cancer Institute. Physician Data Query (PDQ). Pituitary Tumors Treatment. 2012. Accessed at on April 9, 2014.

Ostrom QT, Gittleman H, Farah P, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States 2006-2010. Neuro-Oncol. 2013 Nov; 15(sup 2): ii1 – ii56.

Ragel BT, Couldwell WT. Pituitary carcinoma: A review of the literature. Neurosurg Focus. 2004;16: E7.

Tritos NA, Biller BM. Advances in medical therapies for Cushing’s syndrome. Discov Med. 2012;13:171-179.

Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006; 312:1228-1230.